United Therapeutics (UTHR) Interest Expenses (2009 - 2026)

United Therapeutics has disclosed Interest Expenses across 18 years of filings, most recently posting $3.0 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $3.0 million, down 50.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.4 million (down 54.06% YoY), and the FY2025 annual result was $19.5 million, down 54.55% from the prior year.
• Interest Expenses came in at $3.0 million for Q1 2026 at United Therapeutics, down from $3.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $15.6 million in Q3 2023 to a low of $3.0 million in Q3 2025.
• The 5-year median for Interest Expenses is $9.2 million (2022), against an average of $9.2 million.
• Across the five-year window, Interest Expenses jumped 193.62% in 2023 and tumbled 70.3% in 2025, its largest moves.
• United Therapeutics' Interest Expenses stood at $12.3 million in 2022, then advanced by 22.76% to $15.1 million in 2023, then slumped by 47.68% to $7.9 million in 2024, then plunged by 60.76% to $3.1 million in 2025, then decreased by 3.23% to $3.0 million in 2026.
• The last three Interest Expenses figures came in at $3.0 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.